Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 3, 2011, Pages 550-557

  Kim, Byung Ik ^a   Kim, Hong Joo ^a   Park, Jung Ho ^a   Park, Dong Il ^a   Cho, Yong Kyun ^a   Sohn, Chong Il ^a   Jeon, Woo Kyu ^a   Kim, Hong Soo ^b   Kim, Dong Joon ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Hallym University   (South Korea)

Author keywords

Endotoxin; Gastrointestinal hemorrhage; Infection; Intestinal permeability; Liver cirrhosis; Prophylactic antibiotics

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; HEMOPRESSIN; PROTON PUMP INHIBITOR; TERLIPRESSIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BLOOD TRANSFUSION; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; ENDOSCOPIC SURGERY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION RISK; INTESTINE MUCOSA PERMEABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEPTIC ULCER; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 79951632536     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06490.x     Document Type: Article

References (31)

1. Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995; 108: 1828-34.
2. Rimola A, Bory F, Teres J, Perez-Ayuso RM, Arroyo V, Rodes J. Oral nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5: 463-7.
3. Soriano G, Guarner C, Tomas A etal. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103: 1267-72.
4. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Florent C, Levy VG. Antimicrobial prophylaxis after gastrointestinal hemorrhage for cirrhotic patients with a high risk of infection. Hepatology 1996; 24: 802-6.
5. Hsieh WJ, Lin HC, Hwang SJ etal. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am. J. Gastroenterol. 1998; 93: 962-6.
6. Ruiz del Arbol L, Urman J, Fernandez J etal. Cardiovascular, renal and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-18.
7. Vivas S, Rodríguez M, Palacio MA, Linares A, Alonso JL, Rodrigo L. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig. Dis. Sci. 2001; 46: 2752-7.
8. Hou MC, Lin HC, Liu TT etal. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004; 39: 746-53.
9. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-61.
10. Rimola A, Garcia-Tsao G, Navasa M etal. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J. Hepatol. 2000; 32: 142-53.
11. th meeting of the International Ascites Club. Gut 2005; 54: 718-25.
12. Aparicio JR, Such J, Pascual S etal. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J. Hepatol. 1999; 31: 277-83.
13. Fernandez J, Navasa M, Gomez J etal. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
14. Ortiz J, Vila MC, Soriano G etal. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999; 29: 1064-9.
15. Fernández J, Arbol L, Gómez C etal. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenertology 2006; 131: 1049-56.
16. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect. Immun. 1979; 23: 403-11.
17. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995; 108: 1835-41.
18. Llovet JM, Bartoli R, March F etal. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J. Hepatol. 1998; 28: 307-13.
19. Cirera I, Bauer TM, Navasa M etal. Bacterial translocation of enteric organisms in patients with cirrhosis. J. Hepatol. 2001; 34: 32-7.
20. Wiest R, Rath HC. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract. Res. Clin. Gastroenterol. 2003; 17: 397-425.
21. Gunnarsdottir SA, Sadik R, Shev S etal. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am. J. Gastroenterol. 2003; 98: 1362-70.
22. Ramachandran A, Balasubramanian KA. Intestinal dysfunction in liver cirrhosis: its role in spontaneous bacterial peritonitis. J. Gastroenterol. Hepatol. 2001; 16: 607-12.
23. Budillon G, Parrilli G, Pacella M, Cuomo R, Menzies IS. Investigation of intestine and liver function in cirrhosis using combined sugar loads. J. Hepatol. 1985; 1: 513-24.
24. Ersöz G, Aydin A, Erdem S, Yuksel D, Akarca U, Kumanlioglu K. Intestinal permeability in liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 1999; 11: 409-12.
25. Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur. J. Gastroenterol. Hepatol. 1999; 11: 755-9.
26. Zuckerman MJ, Menzies IS, Path FRC etal. Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes. Dig. Dis. Sci. 2004; 49: 621-6.
27. De Franchis R. Evolving consensus in portal hypertension report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol. 2005; 43: 167-76.
28. Ryan CM, Yarmush ML, Tompkins RG. Separation and quantitation of polyethylene glycols 400 and 3350 from human urine by high-performance liquid chromatography. J. Pharm. Sci. 1992; 81: 350-2.
29. Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988; 35: 373-447.
30. Kang CI, Kim SH, Kim DM etal. Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb. Drug Resist. 2004; 10: 71-6.
31. Lautenbach E, Fishman NO, Bilker WB etal. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch. Intern. Med. 2002; 162: 2469-77.